Safety Assays
Rigorous safety assays for your pipelines
The journey from promising candidate to life-saving therapeutic pivots on rigorous safety evaluation. Our comprehensive suite of in vitro safety assays empowers you to systematically assess potential liabilities early in the development process, ensuring informed decision-making and minimizing risks during clinical trials.
Let us assist you in achieving your candidate’s full potential:
MODELS / SERVICES
The human ether-a-go-go related gene (hERG) encodes the inward rectifying voltage gated potassium channel in the heart (IKr) which is involved in cardiac repolarisation. Inhibition of the hERG current causes QT interval prolongation resulting in potentially fatal ventricular tachyarrhythmia called Torsade de Pointes. A number of drugs have been withdrawn from late stage clinical trials due to these cardiotoxic effects, therefore it is important to identify inhibitors early in drug discovery.
Determine potential hERG inhibition of new chemical entities using the QPatch HTX. We deliver consistent, high quality data with the flexibility to adapt protocols based on specific customer requirements.
Many cell lines developed for use in vitro are metabolically adapted for growth under hypoxic and anaerobic conditions using high glucose media, and derive most of their energy from glycolysis rather than mitochondrial oxidative phosphorylation (a process termed the Crabtree effect). This reduces the cell’s susceptibility to mitochondrial toxicants.
Circumventing the Crabtree effect by replacing glucose with galactose in the cell media increases the reliance of the cells on mitochondrial oxidative phosphorylation to obtain ATP. By comparing the toxic effects of different drugs in the glucose and galactose media, it is possible to detect mitochondrial impairment and identify if this is a primary effect, or secondary to other cytotoxic mechanisms.
We have established in vitro safety assays for compound screening against an assortment of targets involved in toxicity issues in humans.
The targets include:
GPCRs (G-protein coupled receptors)
Ion channels
Nuclear receptors
Transporters
Applications:
Early safety risk assessment
Off target interaction profiling
Reducing safety-related drug attrition
Vital screening in pre-clinical R&D and for IND filing
Committed to quality:
- FDA part 11 compliant
- Animal studies strictly follow AAALAC and ILAC guidelines
- Electronically managed, traceable research data
- Rigorous adherence to international GLP and QA best practices
- Clients have real-time remote monitoring of studies
Want your scientific discoveries to become treatments? PharmaLegacy’s the right partner for you.
Providing Better Data For Critical Oncology Pipeline Decisions
To advance a compound from discovery to clinical, or to halt its development, is a huge and costly decision. For the benefit of you and your company, and for the well-being of patients in need of treatment, that decision needs to be based on correct information.
Download our Integrated In Vitro Oncology Assays brochure and see why over 300 pharmaceutical companies, including many global leaders, trust PharmaLegacy for the unbiased, accurate information they need to make critical oncology pipeline decisions.
We’re ready when you are.
Tell us your pharmacology challenges.